Logo image of DVAX

DYNAVAX TECHNOLOGIES CORP (DVAX) Stock Fundamental Analysis

NASDAQ:DVAX - Nasdaq - US2681582019 - Common Stock - Currency: USD

10.06  +0.14 (+1.41%)

After market: 10.06 0 (0%)

Fundamental Rating

5

Taking everything into account, DVAX scores 5 out of 10 in our fundamental rating. DVAX was compared to 555 industry peers in the Biotechnology industry. Both the profitability and the financial health of DVAX get a neutral evaluation. Nothing too spectacular is happening here. DVAX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

In the past year DVAX was profitable.
DVAX had a positive operating cash flow in the past year.
In multiple years DVAX reported negative net income over the last 5 years.
Of the past 5 years DVAX 4 years had a positive operating cash flow.
DVAX Yearly Net Income VS EBIT VS OCF VS FCFDVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

1.2 Ratios

DVAX's Return On Assets of -6.35% is amongst the best of the industry. DVAX outperforms 86.85% of its industry peers.
Looking at the Return On Equity, with a value of -11.31%, DVAX belongs to the top of the industry, outperforming 87.93% of the companies in the same industry.
Industry RankSector Rank
ROA -6.35%
ROE -11.31%
ROIC N/A
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
DVAX Yearly ROA, ROE, ROICDVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

DVAX's Profit Margin has declined in the last couple of years.
DVAX has a Gross Margin of 82.27%. This is amongst the best in the industry. DVAX outperforms 86.31% of its industry peers.
DVAX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for DVAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
DVAX Yearly Profit, Operating, Gross MarginsDVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

6

2. Health

2.1 Basic Checks

DVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
DVAX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, DVAX has more shares outstanding
DVAX has a worse debt/assets ratio than last year.
DVAX Yearly Shares OutstandingDVAX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DVAX Yearly Total Debt VS Total AssetsDVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

DVAX has an Altman-Z score of 1.47. This is a bad value and indicates that DVAX is not financially healthy and even has some risk of bankruptcy.
DVAX has a Altman-Z score of 1.47. This is in the better half of the industry: DVAX outperforms 68.47% of its industry peers.
The Debt to FCF ratio of DVAX is 4.82, which is a neutral value as it means it would take DVAX, 4.82 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of DVAX (4.82) is better than 93.15% of its industry peers.
DVAX has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.49, DVAX is not doing good in the industry: 73.87% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 4.82
Altman-Z 1.47
ROIC/WACCN/A
WACC7.87%
DVAX Yearly LT Debt VS Equity VS FCFDVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

DVAX has a Current Ratio of 11.93. This indicates that DVAX is financially healthy and has no problem in meeting its short term obligations.
DVAX has a Current ratio of 11.93. This is amongst the best in the industry. DVAX outperforms 82.88% of its industry peers.
A Quick Ratio of 10.84 indicates that DVAX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 10.84, DVAX belongs to the best of the industry, outperforming 80.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.93
Quick Ratio 10.84
DVAX Yearly Current Assets VS Current LiabilitesDVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 325.00% over the past year.
DVAX shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -19.10% yearly.
Looking at the last year, DVAX shows a very strong growth in Revenue. The Revenue has grown by 24.79%.
Measured over the past years, DVAX shows a very strong growth in Revenue. The Revenue has been growing by 51.10% on average per year.
EPS 1Y (TTM)325%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%107.14%
Revenue 1Y (TTM)24.79%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%34.21%

3.2 Future

DVAX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 61.35% yearly.
DVAX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.84% yearly.
EPS Next Y-332.47%
EPS Next 2Y73.55%
EPS Next 3Y61.35%
EPS Next 5YN/A
Revenue Next Year18.52%
Revenue Next 2Y17.67%
Revenue Next 3Y16.55%
Revenue Next 5Y14.84%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DVAX Yearly Revenue VS EstimatesDVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
DVAX Yearly EPS VS EstimatesDVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2 -3

4

4. Valuation

4.1 Price/Earnings Ratio

DVAX is valuated quite expensively with a Price/Earnings ratio of 38.69.
DVAX's Price/Earnings ratio is rather cheap when compared to the industry. DVAX is cheaper than 93.15% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.21. DVAX is valued slightly more expensive when compared to this.
A Price/Forward Earnings ratio of 18.56 indicates a rather expensive valuation of DVAX.
Based on the Price/Forward Earnings ratio, DVAX is valued cheaper than 92.97% of the companies in the same industry.
DVAX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.70.
Industry RankSector Rank
PE 38.69
Fwd PE 18.56
DVAX Price Earnings VS Forward Price EarningsDVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

DVAX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. DVAX is cheaper than 94.05% of the companies in the same industry.
Industry RankSector Rank
P/FCF 22.36
EV/EBITDA N/A
DVAX Per share dataDVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

DVAX's earnings are expected to grow with 61.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y73.55%
EPS Next 3Y61.35%

0

5. Dividend

5.1 Amount

No dividends for DVAX!.
Industry RankSector Rank
Dividend Yield N/A

DYNAVAX TECHNOLOGIES CORP

NASDAQ:DVAX (7/1/2025, 8:17:41 PM)

After market: 10.06 0 (0%)

10.06

+0.14 (+1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners108.37%
Inst Owner Change-1.56%
Ins Owners0.52%
Ins Owner Change0.58%
Market Cap1.21B
Analysts80
Price Target24.3 (141.55%)
Short Float %12.71%
Short Ratio7.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-34.97%
Min EPS beat(2)-86.66%
Max EPS beat(2)16.71%
EPS beat(4)3
Avg EPS beat(4)-11.24%
Min EPS beat(4)-86.66%
Max EPS beat(4)21.41%
EPS beat(8)6
Avg EPS beat(8)91.96%
EPS beat(12)9
Avg EPS beat(12)84.56%
EPS beat(16)10
Avg EPS beat(16)32.97%
Revenue beat(2)0
Avg Revenue beat(2)-4.07%
Min Revenue beat(2)-4.19%
Max Revenue beat(2)-3.96%
Revenue beat(4)0
Avg Revenue beat(4)-4.79%
Min Revenue beat(4)-6.08%
Max Revenue beat(4)-3.96%
Revenue beat(8)3
Avg Revenue beat(8)1.24%
Revenue beat(12)7
Avg Revenue beat(12)8.29%
Revenue beat(16)9
Avg Revenue beat(16)10.65%
PT rev (1m)-0.75%
PT rev (3m)-2.38%
EPS NQ rev (1m)14.25%
EPS NQ rev (3m)3.35%
EPS NY rev (1m)-445.71%
EPS NY rev (3m)-221.66%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.93%
Valuation
Industry RankSector Rank
PE 38.69
Fwd PE 18.56
P/S 4.1
P/FCF 22.36
P/OCF 19.01
P/B 2.28
P/tB 2.28
EV/EBITDA N/A
EPS(TTM)0.26
EY2.58%
EPS(NY)0.54
Fwd EY5.39%
FCF(TTM)0.45
FCFY4.47%
OCF(TTM)0.53
OCFY5.26%
SpS2.45
BVpS4.42
TBVpS4.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.35%
ROE -11.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.27%
FCFM 18.34%
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
F-Score5
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 4.82
Debt/EBITDA N/A
Cap/Depr 117.09%
Cap/Sales 3.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.93
Quick Ratio 10.84
Altman-Z 1.47
F-Score5
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)107.38%
Cap/Depr(5y)141.26%
Cap/Sales(3y)1.68%
Cap/Sales(5y)6.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)325%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%107.14%
EPS Next Y-332.47%
EPS Next 2Y73.55%
EPS Next 3Y61.35%
EPS Next 5YN/A
Revenue 1Y (TTM)24.79%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%34.21%
Revenue Next Year18.52%
Revenue Next 2Y17.67%
Revenue Next 3Y16.55%
Revenue Next 5Y14.84%
EBIT growth 1Y56.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year356.6%
EBIT Next 3Y104.13%
EBIT Next 5YN/A
FCF growth 1Y-59.6%
FCF growth 3Y-43.07%
FCF growth 5YN/A
OCF growth 1Y-54.83%
OCF growth 3Y-41.69%
OCF growth 5YN/A